Note 6 - Research and Development Rebate Receivable	3 Months Ended
Mar. 31, 2022
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: RESEARCH AND DEVELOPMENT REBATE RECEIVABLE On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities including our Phase 1 and Phase 2 Endoxifen and COVID-19 clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. The Australian R&D tax incentive program is a self-assessment process, and as such, the Australian Government has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, and as a result of the review and failure of a related appeal a qualified program and related expenditures were disqualified, the respective R&D rebates could be recalled with penalties and interest. The Company uses the grant accounting model by analogy to International Accounting Standards (IAS) 20 to account for the cash rebates received by the Australian government. During the three months ended March 31, 2022 and 2021, the Company incurred qualified R&D expenses in Australia of $354 and $270, respectively. During the quarter ended March 31, 2022 and year ended December 31, 2021, the Company collected R&D cash rebates of $563 and $0, respectively. At March 31, 2022 and December 31, 2021, we had a total research and development rebate receivable of $668 and $1,072, respectively. The rebate reduced the Research and Development expense line item on the Condensed Consolidated Statements of Operations by $140 and $107 for the three months ended March 31, 2022 and 2021, respectively. The Company had realized (losses) and gains on foreign currency exchange, related to the research and development rebate receivable balance, during the three months ended March 31, 2022 and March 31, 2021, of $28 and $6, respectively, which is included in Other expense, net in the Condensed Consolidated Statements of Operations.

Note 6 - Research and Development Rebate Receivable

3 Months Ended

Mar. 31, 2022

Research and Development Tax Rebate Receivable [Text Block]

NOTE 6: RESEARCH AND DEVELOPMENT REBATE RECEIVABLE

On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities including our Phase 1 and Phase 2 Endoxifen and COVID-19 clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. The Australian R&D tax incentive program is a self-assessment process, and as such, the Australian Government has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, and as a result of the review and failure of a related appeal a qualified program and related expenditures were disqualified, the respective R&D rebates could be recalled with penalties and interest. The Company uses the grant accounting model by analogy to International Accounting Standards (IAS) 20 to account for the cash rebates received by the Australian government. During the three months ended March 31, 2022 and 2021, the Company incurred qualified R&D expenses in Australia of $354 and $270, respectively. During the quarter ended March 31, 2022 and year ended December 31, 2021, the Company collected R&D cash rebates of $563 and $0, respectively. At March 31, 2022 and December 31, 2021, we had a total research and development rebate receivable of $668 and $1,072, respectively. The rebate reduced the Research and Development expense line item on the Condensed Consolidated Statements of Operations by $140 and $107 for the three months ended March 31, 2022 and 2021, respectively.

The Company had realized (losses) and gains on foreign currency exchange, related to the research and development rebate receivable balance, during the three months ended March 31, 2022 and March 31, 2021, of $28 and $6, respectively, which is included in Other expense, net in the Condensed Consolidated Statements of Operations.